We therefore speculate that Fbxo16-deficiency in humans may cause autoimmune diseases and that the Fbxo16/PDLIM2-mediated pathway to terminate NF-κB activation could be the molecular tool for the development of the new therapy of these diseases. This evidence concerns the gene NFKB1 and autoimmune disease.